Objective: To investigate the application value of sufentanil combined with etomidate in anesthesia for children with congenital heart disease. Methods: Totally 96 children with congenital heart disease admitted into our hospital from Jun. 2016 to Sept. 2018 were randomly divided into the experimental group and the control group

with 48 cases in each group. The control group was treated with sufentanil and the experimental group received sufentanil combined with etomidate. Heart rate (HR)

mean arterial pressure (MAP)

systolic blood pressure (SBP) and diastolic blood pressure (DBP) before anesthesia (t1)

10 min after anesthesia induction (t2)

intubation (t3)

skin incision (t4)

posterior sternum (t5) and after surgery (t6) of two groups were compared. Anesthesia effect was evaluated by agitation score

postoperative recovery time and extubation time. The incidence of adverse drug reactions was observed after surgery of 24 h. Results: There was no significant difference in HR

MAP

SBP and DBP between two groups (P>0.05). There was no significant difference in HR during the perioperative period (t1~t6

P>0.05). The MAP

SBP and DBP of two groups had a downward trend after induction of anesthesia and intubation

and the decline in the experimental group was smaller. The agitation score

recovery time

extubation time and incidence of postoperative adverse drug reactions in the experimental group were lower than or shorter than those in the control group (P<0.05). Conclusion: The anesthesia effect of sufentanil combined with etomidate for pediatric congenital heart disease is stable and safe

sufentanil combined with etomidate can improve the anesthesia quality of surgery.